Matt Levy

Image of Matthew Levy

Matt Levy is Patent Counsel at the Computer and Communications Industry Association, where he handles legal, policy advocacy, and regulatory matters related to patents and is lead blogger for CCIA’s Patent Progress. He is recognized as an expert on patent litigation reform and is cited and quoted widely on the issue.

Matt joined the CCIA in 2013 from private practice, where he got first-hand experience in both patent prosecution and patent litigation, including defending clients against patent assertion entities.

Matt graduated from the Georgetown University Law Center magna cum laude with the Order of the Coif, winning the ABA/BNA Award for Excellence in Intellectual Property. He received a Master’s in Computer Science from the University of Kentucky, where he won the Presidential Fellowship twice. His research at UK was in computational complexity theory and artificial intelligence. He received a Bachelor’s degree in Computer Science from the University of Southern Maine.

Before law school, Matt was a software engineer at IBM in Lexington, KY, as part of the team that developed and maintained Lotus Sametime, IBM’s real-time messaging and conferencing product. He is co-inventor on U.S. Patent No. 8,521,830.

Matt is still a software developer in his spare time. He developed an app for the iPad, Federal Local Rules.

Matt is also a blues guitarist.

Posts by Matt Levy

An Article About the PTAB You Must Read

I’ve written about a number of times (e.g., here, here, and here) because it’s an incredibly useful tool for dealing with bad patents. Now, Scott Graham and Lisa Shuchman have done a great piece at on the judges at the Patent Trial and Appeals Board (registration required) that I strongly recommend. Here’s a taste, but…

I Called It: Kyle Bass’s First Two IPR Petitions Fail

Kyle Bass, the hedge fund manager who filed a number of inter partes review petitions against pharmaceutical companies, has struck terror into the shriveled hearts of the pharmaceutical industry. The first petitions he filed were against Acorda Therapeutics, and its stock dropped on the news. The pharmaceutical industry immediately started lobbying to change IPR procedures…

Inter Partes Review and Pharma

Here’s a video I’ve done to explain why the pharmaceutical companies’ campaign against inter partes review is disingenuous at best: You can read more about IPRs here. Note: There was a comment on Twitter pointing out that I don’t discuss Kyle Bass and his hedge fund’s attacks against some pharmaceutical patents using inter partes review.…